Osteoprotegerin As a Marker of Atherosclerosis in Diabetic Patients

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2013 Feb 13

PMID 23401681

Citations 17

Authors

Areti Augoulea

Nikolaos Vrachnis

Irene Lambrinoudaki

Konstantinos Dafopoulos

Zoe Iliodromiti

Angelos Daniilidis

Michail Varras

Andreas Alexandrou

Efthymios Deligeoroglou

George Creatsas

Affiliations

Soon will be listed here.

Abstract

Atherosclerosis is the principal cause of cardiovascular disease (CVD) and has many risk factors, among which is diabetes. Osteoprotegerin (OPG) is a soluble glycoprotein, involved in bone metabolism. OPG is also found in other tissues, and studies have shown that it is expressed in vascular smooth muscle cells. OPG has been implicated in various inflammations and also has been linked to diabetes mellitus. Increased serum OPG levels were found in patients with diabetes and poor glycemic control. Furthermore, prepubertal children with type 1 diabetes have significantly increased OPG levels. Receptor activator of nuclear factor kappa-B ligand (RANKL) is not found in the vasculature in normal conditions, but may appear in calcifying areas. OPG and RANKL are important regulators of mineral metabolism in both bone and vascular tissues. Few data are available on the relationship between plasma OPG/RANKL levels and endothelial dysfunction as assessed using noninvasive methods like ultrasound indexes, neither in the general population nor, more specifically, in diabetic patients. The aim of our review study was to investigate, based on the existing data, these interrelationships in order to identify a means of predicting, via noninvasive methods, later development of endothelial dysfunction and vascular complications in diabetic patients.

Citing Articles

A machine learning based approach to identify carotid subclinical atherosclerosis endotypes.

Chen Q, Bergman O, Ziegler L, Baldassarre D, Veglia F, Tremoli E Cardiovasc Res. 2023; 119(16):2594-2606.

PMID: 37475157 PMC: 10730242. DOI: 10.1093/cvr/cvad106.

Markers of Restenosis after Percutaneous Transluminal Balloon Angioplasty in Patients with Critical Limb Ischemia.

Sobolevskaya E, Shumkov O, Smagin M, Guskov A, Malysheva A, Atuchin V Int J Mol Sci. 2023; 24(10).

PMID: 37240440 PMC: 10219416. DOI: 10.3390/ijms24109096.

Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review.

Biscetti F, Cecchini A, Rando M, Nardella E, Gasbarrini A, Massetti M Atheroscler Plus. 2023; 46:1-14.

PMID: 36643723 PMC: 9833249. DOI: 10.1016/j.athplu.2021.10.003.

Serum osteoprotegerin level in hemodialysis patients using low-flux reused dialyzer in relation to atherosclerosis.

Do Van T, Nguyen Minh T, Dao Bui Quy Q, Quoc T, Nguyen Duy T, Trung K J Clin Lab Anal. 2021; 35(8):e23886.

PMID: 34173983 PMC: 8373337. DOI: 10.1002/jcla.23886.

The Effect of Thyrotropin-Releasing Hormone and Antithyroid Drugs on Fetal Thyroid Function.

Vrachnis N, Tsonis O, Vrachnis D, Antonakopoulos N, Paltoglou G, Barbounaki S Children (Basel). 2021; 8(6).

PMID: 34071168 PMC: 8228147. DOI: 10.3390/children8060454.

References

Hofbauer L, Schoppet M . Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004; 292(4):490-5. DOI: 10.1001/jama.292.4.490. View

Semb A, Ueland T, Aukrust P, Wareham N, Luben R, Gullestad L . Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009; 29(6):975-80. DOI: 10.1161/ATVBAHA.109.184101. View

Ovchinnikova O, Gylfe A, Bailey L, Nordstrom A, Rudling M, Jung C . Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice--brief report. Arterioscler Thromb Vasc Biol. 2009; 29(10):1478-80. DOI: 10.1161/ATVBAHA.109.188185. View

Jarvisalo M, Raitakari M, Toikka J, Putto-Laurila A, Rontu R, Laine S . Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004; 109(14):1750-5. DOI: 10.1161/01.CIR.0000124725.46165.2C. View

Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M . Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond). 2005; 109(4):389-95. DOI: 10.1042/CS20050058. View

Carnevale V, Romagnoli E, DErasmo E . Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev. 2004; 20(3):196-204. DOI: 10.1002/dmrr.449. View

Bots M, Hoes A, Koudstaal P, Hofman A, Grobbee D . Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997; 96(5):1432-7. DOI: 10.1161/01.cir.96.5.1432. View

Terekeci H, Senol M, Top C, Sahan B, Celik S, Sayan O . Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes. 2008; 117(3):119-23. DOI: 10.1055/s-0028-1085425. View

Lieb W, Gona P, Larson M, Massaro J, Lipinska I, Keaney Jr J . Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol. 2010; 30(9):1849-54. PMC: 3039214. DOI: 10.1161/ATVBAHA.109.199661. View

10.

Xiang G, Xu L, Zhao L, Yue L, Hou J . The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes. 2006; 55(7):2126-31. DOI: 10.2337/db06-0231. View

11.

Tarim E, Yigit F, Kilicdag E, Bagis T, Demircan S, Simsek E . Early onset of subclinical atherosclerosis in women with gestational diabetes mellitus. Ultrasound Obstet Gynecol. 2006; 27(2):177-82. DOI: 10.1002/uog.2687. View

12.

Poulsen M, Nybo M, Dahl J, Hosbond S, Poulsen T, Johansen A . Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol. 2011; 10:76. PMC: 3163516. DOI: 10.1186/1475-2840-10-76. View

13.

Schoppet M, Sattler A, Schaefer J, Herzum M, Maisch B, Hofbauer L . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88(3):1024-8. DOI: 10.1210/jc.2002-020775. View

14.

Davis P, Dawson J, RILEY W, Lauer R . Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation. 2001; 104(23):2815-9. DOI: 10.1161/hc4601.099486. View

15.

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

16.

Lane H, Smith J, Davies J . Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2007; 2(1):19-30. PMC: 1993970. DOI: 10.2147/vhrm.2006.2.1.19. View

17.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

18.

Shargorodsky M, Boaz M, Luckish A, Matas Z, Gavish D, Mashavi M . Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women. Atherosclerosis. 2008; 204(2):608-11. DOI: 10.1016/j.atherosclerosis.2008.10.024. View

19.

Malyankar U, Scatena M, Suchland K, Yun T, Clark E, Giachelli C . Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000; 275(28):20959-62. DOI: 10.1074/jbc.C000290200. View

20.

Abdelghaffar S, El Amir M, El Hadidi A, El Mougi F . Carotid intima-media thickness: an index for subclinical atherosclerosis in type 1 diabetes. J Trop Pediatr. 2005; 52(1):39-45. DOI: 10.1093/tropej/fmi071. View